2025年第一次临时 股东大会 会议资料 会 议 时 间 ： 2025年 9月 22日 2 0 2 5 年 第 一 次 临 时 股 东 大 会 资 料 2025年第一次临时股东大会议程 1 一、主持人宣布会议开始，致欢迎词 二、宣读参会须知 三、会议审议事项 议案 1、关于 2025 年度日常关联交易预计的议案； 议案 2、关于变更会计师事务所的议案； 议案 3、关于补选公司第十届董事会董事的议案。 四、报告现场会议到会股东及代表股权情况，宣布投票表决程序，对所审议案进行表 决 五、股东与公司董事、监事、高级管理人员交流 六、总监票人宣布表决结果 七、见证律师宣读法律意见书 八、主持人宣布会议结束 2 0 2 5 年 第 一 次 临 时 股 东 大 会 资 料 股东参会须知 各位股东： 本次股东大会采取现场投票和网络投票相结合的方式召开。 网络投票的流程和方法请参照公司 2025 年 9 月 17 日刊登在《中国证券报》《证 券时报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn）上的《关于 2025 年第 一次临时股东大会取消部分提案暨股东大会的补充通知》中的附件一"参加网络投票 的具体操作 ...

证券代码：000590 证券简称：启迪药业 公告编号：2025-039 启迪药业集团股份公司 第十届董事会临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 启迪药业集团股份公司（以下简称"公司"）第十届董事会临时会议于 2025 年 9 月 16 日以通讯表决方式召开。会议应参加董事 5 人，实参加表决董事 5 人， 无委托出席情况。本次会议的召集和召开符合有关法律、法规和《公司章程》的 规定。经与会董事认真审议并表决，通过如下事项： 一、审议通过《关于取消 2025 年第一次临时股东大会部分提案的议案》 取消部分提案的情况说明： 1、取消提案的名称 2025 年 9 月 17 日 议案 1.00《关于拟变更公司名称并修改<公司章程>的议案》 2、提案取消的原因 近日，公司提交的"古汉养生健康产业集团股份公司"名称变更方案尚未获 得市场监督管理部门审核通过，公司名称变更方案存在不确定性，经审慎考虑， 董事会决定取消该提案。本次取消提案的程序符合《上市公司股东大会规则》和 《公司章程》等有关规定。 3、除上述取消的提案外，公司 2025 年第一次 ...

Group 1 - The core point of the article is that Tsinghua Tongfang (启迪药业) announced a temporary board meeting on September 16, 2025, to discuss the cancellation of certain proposals for the first temporary shareholders' meeting of 2025 [1] - For the first half of 2025, Tsinghua Tongfang's revenue composition shows that traditional Chinese medicine and health products accounted for 94.02%, while other products made up 5.98% [1] - As of the report date, Tsinghua Tongfang has a market capitalization of 3 billion yuan [1]

Core Points - Company will participate in the "2025 Hunan Listed Companies Investor Online Reception Day and Semi-Annual Performance Briefing" event [1] - The event aims to enhance interaction with investors and will be held online [1] - Investors can participate through the "Panjing Roadshow" website, WeChat public account, or the Panjing Roadshow APP [1] - The online interaction time is scheduled for September 19, 2025, from 15:40 to 17:00 [1] - Company executives will communicate with investors regarding their concerns during the event [1]

证券代码：000590 证券简称：启迪药业 公告编号：2025-038 启迪药业集团股份公司 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日暨半 年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，启迪药业集团股份公司（以下简称"公 司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司联 合举办的"资本聚湘江 楚光耀新程——2025 年湖南辖区上市公司投资者网上集 体接待日暨半年度业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，投资者网上在线互动时间为 2025 年 9 月 19 日(星期 五)15:40-17:00。届时公司高管等相关人员将在线就投资者关心的问题，与投资 者进行沟通与交流，欢迎广大投资者踊跃参与。 特此公告。 启迪药业集团股份公司 董事会 2025 年 9 月 13 日 ...

Core Viewpoint - Tsinghua Tongfang Pharmaceutical Group Co., Ltd. plans to hold its first extraordinary general meeting of shareholders for 2025 on September 22 to discuss changes including the company name, amendments to the Articles of Association, and daily related transactions [1] Group 1: Company Changes - Hunan Sailuxian Management Consulting Service Partnership has become the new actual controller of Tsinghua Tongfang Pharmaceutical, initiating significant transformation measures to inject new vitality into the listed company [1] - The company name will be changed from Tsinghua Tongfang Pharmaceutical Group Co., Ltd. to Guhansheng Health Industry Group Co., Ltd. to better reflect its commitment to the health and wellness sector [1] - The board of directors will see new members, including Jiang Lin, founder of Hunan Hengchang Pharmaceutical Group, and Deputy Chairman Zhou Yanqi, which is expected to bring millions of yuan in orders in the second half of the year [1] Group 2: Strategic Vision - The name change aims to enhance market recognition of the "Guhan" brand and demonstrate the company's extensive experience and achievements in the health and wellness field [1] - The collaboration between Hengchang Pharmaceutical and Tsinghua Tongfang is expected to address the company's sales channel shortcomings, facilitating national market expansion and increasing revenue scale and capacity utilization [1] - Jiang Lin emphasized the importance of humility and crisis awareness among employees, encouraging them to become proactive contributors to the company's mission of redefining the pharmaceutical industry [1]

Group 1 - The core point of the announcement is that TUS Pharmaceutical Group Co., Ltd. plans to engage in daily related transactions with its shareholder Hunan Sailoxian Management Consulting Partnership (Limited Partnership) and its related party Hunan Hengchang Pharmaceutical Group Co., Ltd., with an estimated transaction amount not exceeding 50 million yuan for the year 2025 [2][3][29] - The related transactions are deemed necessary for the company's normal business operations and are conducted under fair and reasonable principles, ensuring no harm to the interests of the company and its shareholders [2][10] - The board of directors has approved the proposal for the related transactions, which will be submitted to the shareholders' meeting for further approval, with the related shareholder Hunan Sailoxian required to abstain from voting [3][10][29] Group 2 - The expected related transactions will involve the sale of pharmaceuticals, contract manufacturing services, and research and development services between the company and Hengchang Pharmaceutical [8][9] - Hengchang Pharmaceutical is recognized as a strong player in the domestic pharmaceutical distribution sector, which will complement the company's sales network and enhance its revenue potential [9][10] - The independent directors of the company unanimously agreed that the proposed related transactions align with the company's operational needs and do not harm the interests of minority shareholders [10][23] Group 3 - The company is also planning to change its name to "Guhan Health Industry Group Co., Ltd." to better reflect its main business and enhance brand recognition among consumers and investors [12][13] - The name change requires approval from the shareholders' meeting and registration with the market supervision authority, with the final name subject to approval [13][18] - The company will continue to operate under its existing securities code, ensuring no disruption to its trading status [13][18]

Group 1 - The company held a temporary board meeting on September 4, 2025, where several key resolutions were passed, including the election of new board members and a proposed name change [1][3][11] - The company plans to change its name to "Gu Han Health Industry Group Co., Ltd." to better reflect its main business and enhance brand recognition [3][17][19] - The board approved an estimated daily related party transaction amounting to no more than 50 million yuan for the year 2025, involving sales and services with a related party [5][23][29] Group 2 - The company will hold its first temporary shareholders' meeting on September 22, 2025, to discuss the resolutions passed by the board [7][34][41] - The meeting will include provisions for both on-site and online voting, ensuring broader participation from shareholders [36][37][38] - Shareholders associated with the related party must abstain from voting on specific resolutions to maintain compliance with regulations [42][24]

Group 1 - The core point of the article is that Qidi Pharmaceutical announced the approval of the expected daily related transactions for the year 2025 during the temporary meeting of its tenth supervisory board [2] Group 2 - The announcement was made on the evening of September 5 [2] - The decision was made during a temporary meeting of the supervisory board [2] - The company is preparing for its future financial planning and related transactions [2]

Group 1 - The core point of the article is that Qidi Pharmaceutical announced the approval of multiple resolutions, including the election of new board members during the temporary meeting of its tenth board of directors [2] Group 2 - The announcement was made on the evening of September 5, indicating a significant corporate governance update [2] - The resolutions passed include the proposal to supplement the board of directors, which may impact the company's strategic direction and management [2] - This move reflects the company's ongoing efforts to enhance its governance structure and adapt to market conditions [2]